PMID- 10088163
OWN - NLM
STAT- MEDLINE
DCOM- 19990624
LR  - 20190905
IS  - 0143-3636 (Print)
IS  - 0143-3636 (Linking)
VI  - 20
IP  - 2
DP  - 1999 Feb
TI  - 111In-labelled bleomycin complex for the differentiation of high- and low-grade 
      gliomas.
PG  - 145-52
AB  - The aim of this study was to evaluate 111In-labelled bleomycin complex 
      (111In-BLMC) SPET in the differentiation of high- and low-grade gliomas. Nineteen 
      glioma patients, 14 with high-grade and five with low-grade tumours, were studied 
      1, 4 and 24 h after the injection of 111In-BLMC. In the high-grade glioma group, 
      there was significant uptake of 111In-BLMC in 12 patients and no uptake in two 
      patients based on the visual classification of SPET images at 4 and 24 h. In the 
      low-grade glioma group, one patient had low uptake at 4 and 24 h, but the other 
      four patients showed no visible uptake. The mean tumour to extracerebral 
      circulation activity ratio (T/Cr) at 4 h was 0.13 +/- 0.10 (n = 5) in low-grade 
      gliomas and 1.7 +/- 1.0 (n = 14) in high-grade gliomas. At 24 h the T/Cr ratios 
      were 0.56 +/- 0.21 and 3.4 +/- 1.7, respectively. The mean tumour to 
      contralateral normal brain activity ratios (T/Br) were 5.0 +/- 3.9 (4 h) and 3.0 
      +/- 2.8 (24 h) in low-grade gliomas, and 37.2 +/- 37.3 (4 h) and 8.3 +/- 8.2 (24 
      h) in high-grade gliomas. These higher T/Br ratios did not, however, result in 
      improved differentiation between the two groups of gliomas; at 4 h the T/Cr and 
      T/Br ratios were of equal value, as two high-grade gliomas would have been 
      misclassified as low-grade, but at 24 h the T/Br ratio resulted in more 
      misclassifications. Our results show that 111In-BLMC can be used in the 
      differentiation of high- and low-grade gliomas and that the selection of the 
      reference area for calculating tumour to non-tumour ratios is important.
FAU - Korppi-Tommola, T
AU  - Korppi-Tommola T
AD  - Department of Radiology, Helsinki University Central Hospital, Finland. 
      tapani.korppi-tommola@huch.fi
FAU - Huhmar, H
AU  - Huhmar H
FAU - Aronen, H J
AU  - Aronen HJ
FAU - Penttila, P
AU  - Penttila P
FAU - Hiltunen, J
AU  - Hiltunen J
FAU - Savolainen, S
AU  - Savolainen S
FAU - Kallio, M E
AU  - Kallio ME
FAU - Liewendahl, K
AU  - Liewendahl K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Nucl Med Commun
JT  - Nuclear medicine communications
JID - 8201017
RN  - 0 (Indium Radioisotopes)
RN  - 0 (Organometallic Compounds)
RN  - 0 (indium-bleomycin)
RN  - 11056-06-7 (Bleomycin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Bleomycin/*analogs & derivatives
MH  - Brain/*diagnostic imaging
MH  - Brain Neoplasms/*diagnostic imaging/pathology
MH  - Data Interpretation, Statistical
MH  - Female
MH  - Glioma/*diagnostic imaging/pathology
MH  - Humans
MH  - *Indium Radioisotopes
MH  - Male
MH  - Middle Aged
MH  - *Organometallic Compounds
MH  - *Tomography, Emission-Computed, Single-Photon
EDAT- 1999/03/24 00:00
MHDA- 1999/03/24 00:01
CRDT- 1999/03/24 00:00
PHST- 1999/03/24 00:00 [pubmed]
PHST- 1999/03/24 00:01 [medline]
PHST- 1999/03/24 00:00 [entrez]
AID - 10.1097/00006231-199902000-00006 [doi]
PST - ppublish
SO  - Nucl Med Commun. 1999 Feb;20(2):145-52. doi: 10.1097/00006231-199902000-00006.